PRO045, 3.0 mg/kg/week ( DrugBank: PRO045 )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
113	筋ジストロフィー	1

113. 筋ジストロフィー

---

臨床試験数 : 646 /  薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01826474 (ClinicalTrials.gov)	January 2013	20/3/2013	Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy	A Phase IIb, Open-label Study to Assess the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Multiple Subcutaneous Doses of PRO045 in Subjects With Duchenne Muscular Dystrophy	Duchenne Muscular Dystrophy	Drug: PRO045, 0.15 mg/kg/week;Drug: PRO045, 1.0 mg/kg/week;Drug: PRO045, 3.0 mg/kg/week;Drug: PRO045, 6.0 mg/kg/week;Drug: PRO045, 9.0 mg/kg/week;Drug: PRO045, selected dose	BioMarin Pharmaceutical	NULL	Terminated	5 Years	18 Years	Male	15	Phase 1/Phase 2	Belgium;France;Italy;Netherlands;United Kingdom